Active, not recruitingPhase 2NCT04554914
A Study to Evaluate Tabelecleucel in Participants With Epstein Barr Virus (EBV) Associated Diseases
Studying Complication after organ transplantation
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Pierre Fabre Medicament
- Principal Investigator
- Glen Lew, MDPierre Fabre Laboratories
- Intervention
- Tabelecleucel(biological)
- Enrollment
- 190 enrolled
- Eligibility
- All sexes
- Timeline
- 2021 – 2028
Study locations (30)
- University of California Los Angeles (UCLA) (Adults and Pediatrics), Los Angeles, California, United States
- Children's Hospital of Orange County (Pediatrics [up to 25 years old]), Orange, California, United States
- Lucile Packard Children's Hospital Stanford (Pediatrics only), Palo Alto, California, United States
- University of California Davis Comprehensive Cancer Center (Adults and Pediatrics), Sacramento, California, United States
- Sylvester Comprehensive Cancer Center/ University of Miami, Miami, Florida, United States
- Moffit Cancer Center (Adults only), Tampa, Florida, United States
- Children's Healthcare of Atlanta (Pediatrics only [up to 25 years old]), Atlanta, Georgia, United States
- Emory University/Winship Cancer Institute (Adults [>= 16 years]), Atlanta, Georgia, United States
- Ann & Robert H. Lurie Children's Hospital of Chicago (Pediatrics only), Chicago, Illinois, United States
- University of Maryland Medical Center (Adults only), Baltimore, Maryland, United States
- Dana Farber Cancer Institute (DFCI) (Adults and Pediatrics), Boston, Massachusetts, United States
- University of Michigan Rogel Cancer Center (Adults and Pediatrics), Ann Arbor, Michigan, United States
- University of Minnesota (Adults only), Minneapolis, Minnesota, United States
- Washington University in St. Louis (Adults only), St Louis, Missouri, United States
- Columbia University Irving Medical Center (Adults only), New York, New York, United States
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04554914 on ClinicalTrials.govOther trials for Complication after organ transplantation
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT06872333Allo HSCT for High Risk HemoglobinopathiesMasonic Cancer Center, University of Minnesota
- RECRUITINGNANCT06512545Modified Second Haplo-transplantation for Graft FailurePeking University People's Hospital
- RECRUITINGNANCT06512519Second Haplo-transplantation for Graft FailurePeking University People's Hospital
- RECRUITINGNCT05836922Association Between Renal Regional Oxygen Saturation Measured by Near-InfraRed Spectroscopy and Postoperative Renal Failure After Lung Transplantation Surgery: A Pilot StudyAssistance Publique Hopitaux De Marseille
- RECRUITINGNANCT06386198HEalth Advocate for Liver Transplantation: Improving Transition of Care for Adolescent Liver Transplant RecipientsUniversity of California, San Francisco
- RECRUITINGEARLY PHASE1NCT04469842Early Use of Long-acting Tacrolimus in Lung Transplant RecipientsVanderbilt University Medical Center
- ENROLLING BY INVITATIONNCT05818644Hepatic Artery Stenosis and Thrombosis After Liver Transplantation in ChildrenUniversity Medical Center Groningen
- ACTIVE NOT RECRUITINGPHASE4NCT05557370Immunogenicity of HPV Vaccine in Transplant Recipients.Medical College of Wisconsin
See all trials for Complication after organ transplantation →